medigraphic.com
ISSN 1684-1824 (Electronic)

2019, Number 3

<< Back Next >>

Rev Méd Electrón 2019; 41 (3)

Arterial hypertension control: still without definition

Arredondo BAE, de Quezada LF, Guerrero JG

Language: Spanish
References: 29
Page: 698-707
PDF size: 709.32 Kb.


ABSTRACT

The debate on the maintained arterial tension measure, and on the measure to obtain through the long term treatment, is currently a problem for the medical practitioner, due to the variation of arterial tension during the day at different hours because of the patients circadian cycle, and due to variations in different days according to the proper patient’s situations or the environment around it, and the different seasons of the year. They make it difficult to know when arterial tension is within the parameters accepted as “controlled”. The authors carried out a systematic review of documents published in PubMed, Scielo and MEDLINE in the period 2012-2018, both in English and Spanish, on the arterial tension definition, evaluation and management. The guidelines agree in taking arterial tension measures in different moments for the diagnosis, but not in defining tension control. Defining tension control should include a time dimension of at least a year, and a minimal proportion of measures within the parameters recognized as non-pathological or optimal on the basis of measures taken at least every three months. Therefore, the authors suggest that an annual profile of the arterial tension parameters should be considered as a minimal requirement to evaluate arterial hypertension control.


REFERENCES

  1. Zipes DP, Libby P, Bonow RO, et al. Braunwald's Heart Disease E-Book: A Textbook of Cardiovascular Medicine. New York: Edi. Elsevier Health Sciences; 2018.

  2. Xie X, Atkins E, LV J. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. The Lancet 2016;387(10017):435–43. Citado en PubMed; PMID: 26559744.

  3. Ministerio de Salud Pública. Anuario Estadístico de Salud. Dirección de Registros médicos y Estadísticas [Internet]. La Habana: Ministerio de Salud Pública [citado 20/08/2018];2018.Disponible en: http://bvscuba.sld.cu/anuario-estadistico-de-cuba/

  4. Basu S, Sussman JB, Hayward RA. Detecting heterogeneous treatment effects to guide personalized blood pressure treatment: a modeling study of randomized clinical trials. Ann Intern Med. 2017;166(5):354-60. Citado en PubMed; PMID: 28055048.

  5. Atkins ER, Hlth B, Rodgers A. Redefining Blood Pressure Targets. Eur Heart J. [Internet]. 2017 [citado 20/08/2018];38(14):1008-11. Disponible en: https://academic.oup.com/eurheartj/article/38/14/1008/3108833

  6. Heller SB, Shah A K, Guryan J, et al. Thinking, fast and slow? Some field experiments to reduce crime and dropout in Chicago. The Quarterly J Economics. 2017;132(1):1-54. Citado en PubMed; PMID: 29456270.

  7. Croskerry P, Norman GR, Monteiro SD, et al. The causes of errors in clinical reasoning: cognitive biases, knowledge deficits, and dual process thinking. Acad Med. 2017;92(1):23-30. Citado en PubMed; PMID: 27782919.

  8. Modesti PA, Morabito M, Massetti L. Seasonal Blood Pressure Changes. Hypertension. 2013;61(4). Citado en PubMed; PMID: 23381792.

  9. Lewington S, LiMing L, Sherliker P. Seasonal variation in blood pressure and its relationship with outdoor temperature in 10 diverse regions of China: the China Kadoorie Biobank. J Hypertension. 2012;30(7):1383. Citado en PubMed; PMID: 22688260.

  10. Chow CK, Thakkar J, Bennett A, et al. Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review. TheLancet. 2017;389(10073):1035-42. Citado en PubMed; PMID: 28190578.

  11. Mancia G, Rea F, Cuspidi C, et al. Blood pressure control in hypertension. Pros and cons of available treatment strategies. J Hypertens. 2017;35(2):225-33. Citado en PubMed; PMID: 27898507.

  12. Khin MU. FDA Briefing Document. Cardiovascular and Renal Drugs Advisory Committee Meeting [Internet]. USA: FDA; 2014 [citado 20/08/2018]. Disponible en: https://www.fda.gov/media/114447/download

  13. Muth C, Van den Akker M, Glasziou PP. Blood pressure targets in primary care. BMJ. 2016;352:i813. Citado en PubMed; PMID: 26920040.

  14. O’Donovan G, Stensel D, Hamer M, et al. The association between leisure-time physical activity, low HDL-cholesterol and mortality in a pooled analysis of nine population-based cohorts. Eur J Epidemiol. 2017;32(7):559-66. Citado en PubMed; PMID: 28667447.

  15. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2017 Focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDLcholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on expert consensus decision pathways. J Am Coll Cardiol. 2017;70(14):1785-22. Citado en PubMed; PMID: 28886926.

  16. Murray AM, Hsu FC, Williamson JD, et al. ACCORDION MIND: results of the observational extension of the ACCORD MIND randomised trial. Diabetologia. 2017;60(1):69-80. Citado en PubMed; PMID: 27766347.

  17. Johnson KC, Whelton PK, Cushman WC, et al. Blood pressure measurement in SPRINT (systolic blood pressure intervention trial). Hypertension. 2018;71(5):848-57. Citado en PubMed; PMID: 29531173.

  18. Muntner P, Whelton PK. Using predicted cardiovascular disease risk in conjunction with blood pressure to guide antihypertensive medication treatment. J Am Coll Cardiol. 2017;69(19):2446-56. Citado en PubMed; PMID: 28494981.

  19. Weber MA. Blood Pressure Variability and Cardiovascular Prognosis:Implications for Clinical Practice. Eur Heart J. 2017;38(37):2823-6. Citado en PubMed; PMID: 28982228.

  20. Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 2015;313(6):603-15. Citado en PubMed; PMID: 25668264.

  21. Ettehad D, Emdin CA, Kiran A. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022): 957–67. Citado en PubMed; PMID: 26724178.

  22. Drawz PE, Pajewski NM, Bates JT, et al. Effect of intensive versus standard clinicbased hypertension management on ambulatory blood pressure: results from the SPRINT (Systolic Blood Pressure Intervention Trial) ambulatory blood pressure study. Hypertension. 2017;69(1):42-50. Citado en PubMed; PMID: 27849563.

  23. Brugts JJ, Bertrand M, Remme W, et al. The treatment effect of an ace-inhibitor based regimen with perindopril in relation to beta-blocker use in 29 463 patients with vascular disease: a combined analysis of individual data of ADVANCE, EUROPA and PROGRESS trials. Cardiovas Drugs Ther. 2017;31(4):391-400. Citado en PubMed; PMID: 28856537.

  24. James PA, Oparil S, Carter BL. Evidence-based guideline for the management of high blood pressure in adults. Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-20. Citado en PubMed; PMID: 24352797.

  25. Poulter NR, Lackland DT. May Measurement Month: a global blood pressure screening campaign. Lancet. 2017;389(10080):1678-80. Citado en PubMed; PMID: 28463128.

  26. Joseph P, Lonn E, Bosch J, et al. Long-term effects of statins, blood pressurelowering, and both on erectile function in persons at intermediate risk for cardiovascular disease: a substudy of the Heart Outcomes Prevention Evaluation-3 (HOPE-3) randomized controlled trial. Cardiology. 2018;34(1):38-44. Citado en PubMed; PMID: 29275880.

  27. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10–Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens. 2017;35(5):922-44. Citado en PubMed; PMID: 28141660.

  28. Jung O, Gechter JL, Wunder C. Resistant hypertension? Assessment of adherence by toxicological urine analysis. Jhypertension. 2013;31(4):766–74. Citado en PubMed; PMID: 23337469.

  29. Tomaszewski M, White C, Patel P. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart. 2014;100(11):855-61. Citado en PubMed; PMID: 24694797.




2020     |     www.medigraphic.com